Allianz Asset Management
PVLA

Allianz Asset Management’s Palvella Therapeutics PVLA Stock Holding History

Allianz Asset Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-143
Closed -$39K – 2865
2019
Q3 		$39K Sell
143
-1
-0.7% -$387 ﹤0.01% 2709
2019
Q2 		$54K Sell
144
-2
-1% -$597 ﹤0.01% 2654
2019
Q1 		$39K Buy
146
+11
+8% +$2.61K ﹤0.01% 2644
2018
Q4 		$29K Sell
135
-2,177
-94% -$675K ﹤0.01% 2579
2018
Q3 		$1.04M Buy
2,312
+184
+9% +$80K ﹤0.01% 2211
2018
Q2 		$863K Sell
2,128
-215
-9% -$102K ﹤0.01% 2279
2018
Q1 		$1.28M Buy
+2,343
New +$1.45M ﹤0.01% 2110

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Allianz Asset Management's PVLA Position: Q4 2019 in Review

Allianz Asset Management sold out of Palvella Therapeutics (PVLA) in Q4 2019, closing a stake of 143 shares — an estimated $39K sold.

Allianz Asset Management first reported a position in PVLA in Q1 2018 and held it in 7 quarters. The position peaked at $1.28M in Q1 2018. 97 funds tracked by Wall St. Rank hold PVLA as of Q4 2019.

  • Allianz Asset Management reported no remaining Palvella Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Allianz Asset Management sold 143 Palvella Therapeutics shares in Q4 2019, an estimated $39K.
  • Allianz Asset Management first reported a position in Palvella Therapeutics in Q1 2018 and held it in 7 quarters.
  • Allianz Asset Management's Palvella Therapeutics position peaked at $1.28M in Q1 2018.
  • 97 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2019.

Based on Allianz Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.